In 1998, an important mollecular biology studio demonstrated that cells affected by acute lymphoblastic leukemia present an atypical DNA sequence that is different for every patient. Once individualized through a protocol called Minimal Residual Disease (MRD), it is possible to monitor these cells and choose the appropriate treatment dosage. This is the first step towards the personalization and optimization of therapy for this particular disease.

These diagnostics are carried out in Monza at the Tettamanti Research Center for around 400 Italian children per year using advanced molecular biology technology, entirely financed by the Maria Letizia Verga Committee.